Investors

Investor Presentation May 2021

2021 Annual General Meeting

Corporate Profile

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Founded in 1996, the Company is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP.

| (Common Stock)

Stock chart for: SBBP.O. Currently trading at $4.40 with a 52 week high of $6.24 and a 52 week low of $2.00.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement

08/02/21

DUBLIN, Ireland and TREVOSE, Pa. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP) (“ Strongbridge ”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs,...

Read More
Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue

07/29/21

DUBLIN, Ireland and TREVOSE, Pa. , July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP) (“ Strongbridge ”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs,...

Read More

Investors

Investors

Click here for more information on the proposed acquisition of Strongbridge Biopharma plc by Xeris Pharmaceuticals, Inc.

Click here for more information on the SEC Documents Incorporated by Reference

Corporate Profile

Press Releases

Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement

Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue

Upcoming Events